Identification of CD14 as a potential biomarker of hepatocellular carcinoma using iTRAQ quantitative proteomics.

Guo, Jiao; Jing, Rui; Zhong, Jian-Hong; Dong, Xin; Li, Yun-Xi; Liu, Yin-Kun; Huang, Tian-Ren; Zhang, Chun-Yan

Guo, Jiao; Jing, Rui; Zhong, Jian-Hong; Dong, Xin; Li, Yun-Xi; Liu, Yin-Kun; Huang, Tian-Ren; Zhang, Chun-Yan.

Afiliação

Guo J; Experimental Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, PR China.
Jing R; Experimental Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, PR China.
Zhong JH; Hematology Department, Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, PR China.
Dong X; Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, PR China.
Li YX; Experimental Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, PR China.
Liu YK; Oncology Department, Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, PR China.
Huang TR; Cancer Registry Department, People's Hospital of Fusui County, Fusui, Guangxi, PR China.
Zhang CY; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Yangpu, Shanghai, PR China.

Oncotarget ; 8(37): 62011-62028, 2017 Sep 22.

Article em En | MEDLINE | ID: mdl-28977922

Palavras-chave

CD14; biomarker; diagnosis; hepatocellular carcinoma (HCC); iTRAQ

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google